Curis Lifesciences Ltd
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]
- Market Cap ₹ 172 Cr.
- Current Price ₹ 212
- High / Low ₹ 229 / 83.6
- Stock P/E 32.0
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| 35.42 | 35.58 | |
| 32.16 | 27.14 | |
| Operating Profit | 3.26 | 8.44 |
| OPM % | 9.20% | 23.72% |
| 0.34 | 0.31 | |
| Interest | 1.33 | 0.85 |
| Depreciation | 0.73 | 0.68 |
| Profit before tax | 1.54 | 7.22 |
| Tax % | 20.13% | 25.90% |
| 1.23 | 5.36 | |
| EPS in Rs | 24.60 | 107.20 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 336% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Equity Capital | ||
| Reserves | ||
| Total Liabilities | ||
| CWIP | ||
| Investments | ||
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Net Cash Flow | ||
| Free Cash Flow | ||
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Debtor Days | ||
| Inventory Days | ||
| Days Payable | ||
| Cash Conversion Cycle | ||
| Working Capital Days | ||
| ROCE % |
Insights
In beta| Mar 2024 | Mar 2026 | |
|---|---|---|
| Cumulative Product Registrations count |
|
|
| Customer Base count |
||
| Export Revenue Share % |
||
| Number of Countries (Regulatory Footprint) count |
||
| Product Portfolio Size count |
||
| Tablets Capacity Utilization % |
||
Extracted by Screener AI
Documents
Announcements
-
Copy of Newspaper Publication
- Curis Lifesciences will hold its 10th AGM on 29 September 2026 via VC/OAVM; remote e-voting details published.
-
Shareholders meeting
- 10th AGM on 29 Sep 2026; FY2025-26 annual report submitted.
-
Outcome of Board Meeting
- Board approved FY26 Director’s Report, AGM notice, related party transactions; 10th AGM on 29 September 2026.
-
Resignation of Director/KMP/SMP
- Curis Lifesciences Limited has informed about Resignation of Director/KMP/SMP
-
Cessation
- Company Secretary and Compliance Officer Nikhil Purohit resigned effective 3 September 2026.
Concalls
-
Mar 2026PPT
-
Jan 2026Transcript
-
Jan 2026Transcript
Business Overview:[1][2]
CLSL is a WHO-GMP certified pharma company based in Ahmedabad, India. The co. provides healthcare solutions with loan licensing and also contract manufacturing and offers pharma products formulated from solid and liquid forms to deliver adherence to every therapeutic category. Its offerings also include sterile and non-sterile products. The company exports to 10+ countries and has 18k+ customers